MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00210-025-04369-4

Медицинская библиотека · Naunyn-Schmiedeberg's archives of pharmacology · 2025

Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials.

Balbaa Elsayed, Gadelmawla Ahmed Farid, Tawfik Abdelrahman M, Naeem Ahmed, Elbataa Ahmed, Bazzazeh Mohammad, Fatiem Ahmed Ramadan, Ali Khaled, Altobaishat Obieda, Abuelazm Mohamed

СтатьяСистематический обзорМетаанализПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Vascular complications after percutaneous cardiac interventions are a significant cause of morbidity that affects post-procedural prognosis. Data about the efficacy and safety of routine protamine sulphate to prevent these complications remain scarce. Hence, we aim to assess the efficacy and safety of routine protamine sulphate use for heparin reversal in patients undergoing percutaneous cardiac interventions. We systematically searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) until September 2024. The RCTs' quality was assessed using the Cochrane tool (RoB 2). Using R, we pooled dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD), both along the corresponding 95% Confidence interval (CI). PROSPERO ID: (CRD42024593002). Six RCTs with 1,076 patients were eligible. Hemostasis success was significantly higher in the protamine group (RR, 1.06; 95% CI [1.01-1.10]; P = 0.01), and the length of hospital stay was significantly shorter (MD, -0.46; 95% CI [-0.65, -0.26]; P < 0.01). There was no significant difference between both groups in stroke (RR, 0.60; 95% CI [0.18-2.03]; P = 0.41), major bleeding (P = 0.25), minor bleeding (P = 0.11), life-threatening bleeding (P = 0.65), time to ambulation (P = 0.13), all-cause mortality (P = 0.92), hematoma/pseudoaneurysm (P = 0.92), and major vascular complications (P = 0.70). While protamine improved hemostasis success, its effect on reducing bleeding events and time to ambulation was insignificant. Also, reducing the length of hospital stay in the protamine group highlights its potential clinical benefit.

Для цитирования: Balbaa Elsayed, Gadelmawla Ahmed Farid, Tawfik Abdelrahman M, Naeem Ahmed, Elbataa Ahmed, Bazzazeh Mohammad, Fatiem Ahmed Ramadan, Ali Khaled, Altobaishat Obieda, Abuelazm Mohamed. Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials.. Naunyn-Schmiedeberg's archives of pharmacology. 2025. DOI: 10.1007/s00210-025-04369-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.